Solutions of interest include:
- Bifunctional molecules to redirect the interaction between target A and target B (type I)
- Technology to inhibit target A by recruiting shield protein X using bifunctional molecule (type II)
- Methodology for designing the above bifunctional molecules based on protein structure information
- A focused library of bifunctional small molecules useful for screening seeds for the above technologies
- An approach to convert inhibitory antibodies and peptides into small molecules.

Our must-have requirements are:
- Perform computational chemical design based on protein structure and obtain proximity-inducing bifunctional small molecule compounds. (for the 3rd interest)
- A specific example of a compound obtained by applying the methodology to some target must be included.(for the 2nd and 3rd interest)
- Data showing the efficacy of the compound in vitro, using cultured cells. Efficacy means inhibiting the PPI of the target proteins and, as a result, inhibiting its function.

Our nice-to-have requirements are:
- Methodology applicable to multiple targets (two or more targets)
- Oncology-related results such as growth inhibition in cancer cells are not required

What's out of scope:
- Approaches that rely on serendipitous identification, such as phenotype screening or cell-based screening
- Approaches that end with obtaining inhibitory antibodies or inhibitory peptides. The subsequent methodology for converting them into small molecules is important for us.
- Technologies to design inhibitors against a single target (not bifunctional). We are looking for methodologies that are useful for modulating PPI.

Funding is proposal dependent, with up to $ 150K for 12 month project with potential follow-on funding for 1 year.